PERJETA and Herceptin are two HER2-targeted therapies. They work together to treat HER2+ breast cancer alongside chemotherapy. PHESGO works in the same way to treat HER2+ breast cancer. PHESGO also contains hyaluronidase, a protein that helps the body absorb the two medicines and allows them to be given as a single injection under the skin, in just minutes.
In a clinical study, 85% of people preferred PHESGO over PERJETA + Herceptin and the most common reason was less time spent in the clinic. Check out the study here. >
PHESGO is a single ~5 minute injection given under the skin,* while PERJETA + Herceptin are given as an intravenous (IV) infusion in about 60-150 minutes.
*The first dose is given in ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
If you are currently taking PERJETA + Herceptin, you may be eligible to switch to PHESGO.
Ask your doctor if PHESGO is right for you.
Watch Jen’s story to hear more about her experience with HER2+ breast cancer and PHESGO.
Most major insurance plans, including private/commercial and public insurance plans, provide coverage for PHESGO*. There may be options available to help you afford your medicine.
*Data current as of 05/2024. Individual out-of-pocket cost will vary depending on carrier plan.
Your doctor can answer any questions you have about PHESGO.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.